REGN Q1 2023 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.2B+6.6% YoY

Gross Profit

$2.6B82.4% margin

Operating Income

$1.0B31.7% margin

Net Income

$818M25.9% margin

EPS (Diluted)

$7.17

QoQ Revenue Growth

-7.4%

Cash Flow

Operating Cash Flow

$1.4B

Free Cash Flow

$1.2B

Stock-Based Comp.

$239M

Balance Sheet

Total Assets

$30.1B

Total Liabilities

$6.6B

Stockholders' Equity

$23.5B

Cash & Equivalents

$3.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.2B	$3.0B	+6.6%
Gross Profit	$2.6B	$2.5B	+4.8%
Operating Income	$1.0B	$1.3B	-22.1%
Net Income	$818M	$974M	-16.0%

Revenue Segments

Product

$1.7B53%

Collaboration Revenue

$1.4B44%

Product and Service, Other

$116M4%